When a new prescription drug enters the market, the question for employers isnt just does it work? Its what does covering it mean for our people, our plan, and our longterm costs? That question became especially relevant in early 2026, when an oral version of Wegovy entered the market with widespread media coverage
They do not account for the unique concentrations that a 503A compounding pharmacy like Empower provides, and they certainly do not walk you through the syringe math that compounded vials require
Liverrelated outcomes in EPP (observational) A retrospective cohort (n=70) found afamelanotide exposure associated with dosedependent improvements in liverfunction tests (decreased ALAT and bilirubin with more doses in the prior year) and lower PPIX when more recently dosed
This review explores clinical trials in obesity, novel therapeutic targets, and the role of TGF- signaling and vagus nerve modulation in obesity-related liver diseases and HCC
Smoking, diabetes, high blood pressure, high cholesterol, and low activity can all affect blood vessels